Merck's (NYSE:MRK) experimental antibody drug conjugate zilovertamab vedotin, in combination with standard of care, demonstrated encouraging antitumor activity in the phase 2 portion of a study of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback